Lasalocid
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Lasalocid
- DrugBank Accession Number
- DB11423
- Background
Lasalocid is an agent that presents antibacterial and coccidiostat activities. It is produced by strains of Streptomyces lasaliensis.
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
- Weight
- Average: 590.798
Monoisotopic: 590.381868699 - Chemical Formula
- C34H54O8
- Synonyms
- Lasalocid
- External IDs
- RO 2-2985
- RO-2-2985
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The risk or severity of bleeding can be increased when Lasalocid is combined with Acenocoumarol. Ambroxol The risk or severity of methemoglobinemia can be increased when Lasalocid is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Lasalocid is combined with Articaine. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Lasalocid. Benzocaine The risk or severity of methemoglobinemia can be increased when Lasalocid is combined with Benzocaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diterpene glycosides. These are diterpenoids in which an isoprene unit is glycosylated.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Terpene glycosides
- Direct Parent
- Diterpene glycosides
- Alternative Parents
- Diterpenoids / Salicylic acids / Benzoic acids / Fatty alcohols / Ortho cresols / Benzoyl derivatives / Toluenes / 1-hydroxy-4-unsubstituted benzenoids / Oxanes / Beta-hydroxy ketones show 10 more
- Substituents
- 1-hydroxy-4-unsubstituted benzenoid / Alcohol / Aromatic heteromonocyclic compound / Benzenoid / Benzoic acid / Benzoic acid or derivatives / Benzoyl / Beta-hydroxy ketone / Carbonyl group / Carboxylic acid show 27 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Polyether polyketides (LMPK09000002)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- W7V2ZZ2FWB
- CAS number
- 25999-31-9
- InChI Key
- BBMULGJBVDDDNI-OWKLGTHSSA-N
- InChI
- InChI=1S/C34H54O8/c1-9-25(31-21(6)18-34(11-3,42-31)26-16-17-33(40,10-2)23(8)41-26)30(37)22(7)28(35)19(4)12-14-24-15-13-20(5)29(36)27(24)32(38)39/h13,15,19,21-23,25-26,28,31,35-36,40H,9-12,14,16-18H2,1-8H3,(H,38,39)/t19-,21+,22+,23+,25+,26-,28+,31+,33-,34+/m1/s1
- IUPAC Name
- 6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-3-methyloxolan-2-yl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methylbenzoic acid
- SMILES
- [H][C@@](C)(CCC1=C(C(O)=O)C(O)=C(C)C=C1)[C@]([H])(O)[C@]([H])(C)C(=O)[C@]([H])(CC)[C@@]1([H])O[C@@](CC)(C[C@]1([H])C)[C@@]1([H])CC[C@](O)(CC)[C@]([H])(C)O1
References
- General References
- Benson JE, Ensley SM, Carson TL, Halbur PG, Janke BH, Quinn WJ: Lasalocid toxicosis in neonatal calves. J Vet Diagn Invest. 1998 Apr;10(2):210-4. [Article]
- Blanchard PC, Galey FD, Ross F, Landgraf WW, Meyer H, Spiro N: Lasalocid toxicosis in dairy calves. J Vet Diagn Invest. 1993 Apr;5(2):300-2. [Article]
- Shlosberg A, Weisman Y, Klopfer U, Perl S: Neurotoxic action of lasalocid at high doses. Vet Rec. 1985 Oct 12;117(15):394. [Article]
- Espino L, Suarez ML, Mino N, Goicoa A, Fidalgo LE, Santamarina G: Suspected lasalocid poisoning in three dogs. Vet Hum Toxicol. 2003 Oct;45(5):241-2. [Article]
- Hagel RB: Liquid chromatographic determination of lasalocid in premixes. J Assoc Off Anal Chem. 1978 Sep;61(5):1070-3. [Article]
- Fitzgerald PR, Mansfield ME: Efficacy of lasalocid against coccidia in cattle. J Parasitol. 1979 Oct;65(5):824-5. [Article]
- Kronfeld DS: Lasalocid toxicosis is inadequately quantified for horses. Vet Hum Toxicol. 2002 Aug;44(4):245-7. [Article]
- Mitrovic M, Schildknecht EG, Marusich WL: Lasalocid in prevention of turkey coccidiosis. Poult Sci. 1979 Sep;58(5):1154-9. [Article]
- Galitzer SJ, Oehme FW, Bartley EE, Dayton AD: Lasalocid toxicity in cattle: acute clinicopathological changes. J Anim Sci. 1986 May;62(5):1308-16. [Article]
- Segev G, Baneth G, Levitin B, Shlosberg A, Aroch I: Accidental poisoning of 17 dogs with lasalocid. Vet Rec. 2004 Aug 7;155(6):174-6. [Article]
- External Links
- KEGG Drug
- D04671
- ChemSpider
- 4514598
- 1364397
- ChEBI
- 92181
- ChEMBL
- CHEMBL145347
- ZINC
- ZINC000004216707
- PDBe Ligand
- LSD
- Wikipedia
- Lasalocid
- PDB Entries
- 4rzm
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00432 mg/mL ALOGPS logP 4.91 ALOGPS logP 7.67 Chemaxon logS -5.1 ALOGPS pKa (Strongest Acidic) 2.64 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 133.52 Å2 Chemaxon Rotatable Bond Count 13 Chemaxon Refractivity 162.8 m3·mol-1 Chemaxon Polarizability 66.61 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 269.9692175 predictedDarkChem Lite v0.1.0 [M-H]- 227.82211 predictedDeepCCS 1.0 (2019) [M+H]+ 273.9222175 predictedDarkChem Lite v0.1.0 [M+H]+ 229.54584 predictedDeepCCS 1.0 (2019) [M+Na]+ 270.9492175 predictedDarkChem Lite v0.1.0 [M+Na]+ 235.81575 predictedDeepCCS 1.0 (2019)
Drug created at February 25, 2016 18:39 / Updated at February 21, 2021 18:53